# Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

> **NCT00958841** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 118 (actual)

## Conditions studied

- Pancreatic Neoplasm
- Pituitary Neoplasm
- Nelson Syndrome
- Ectopic ACTH Syndrome

## Interventions

- **DRUG:** pasireotide LAR

## Key facts

- **NCT ID:** NCT00958841
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 118 (ACTUAL)
- **Why stopped:** Slow recruitment rate into this study with rare tumors of neuroendocrine origin (enrollment issues)
- **Last updated:** 2016-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00958841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00958841, "Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00958841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*